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Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated
with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant
waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which
increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies.
We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-
matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year
prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more
treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days
versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the
age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores)
with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly
ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF) is the most common lethal inherited
genetic disorder with autosomal recessive inheritance in
Caucasian people. There is a carrier rate of about 1 in 25 and
an incidence of about 1 in 2500 live births. Repeated lung
infection, most commonly due to Pseudomonas aeruginosa,
results in progressive respiratory damage, which almost
inevitably leads to respiratory failure and death.
Methicillin resistant Staphylococcus aureus (MRSA)
was first reported in 1961 in London, UK [1]. It has1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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worldwide. Estimates vary from country to country and
hospital to hospital but between 5% and 50% of S .aureus
isolates in affected hospitals are MRSA. Resistance is
conferred by the mecA gene that encodes for a single
additional penicillin binding protein, PBP2a, with low
affinity for h-lactams [2].
There are many reasons for the emergence of MRSA.
These include host factors, infection control practices and
antimicrobial pressures [3]. Studies in non-CF patients have
identified several risk factors, including previous antibiotic
therapy [4,5], previous hospitalisation [5,6], admission to
ICU [7,8], chronic illness [9], exposure to other patients
known to be colonised with MRSA [10], and presence of
intravenous access devices [5,11]. All of these factors are
applicable to patients with CF.s 4 (2005) 49–52ed by Elsevier B.V. All rights reserved.
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uncertain but reports range from 3% to 10% [12–15] and it
appears to be increasing. Little is also known about the
clinical impact of MRSA in CF. Most studies have found no
correlation with clinical deterioration [12,14], although one
study demonstrated that CF patients colonised with MRSA
required more courses of antibiotics, had poorer chest X-ray
scores, and poorer growth than MRSA-negative controls
[15]. However, the long term impact of MRSA colonisation
remains unknown and some authorities have started to
develop various eradication protocols using antibiotics and
infection control interventions in an attempt to prevent
chronic infection [16,17]. Solis et al. used topical applica-
tion of oral and nebulised vancomycin for 5 days in
conjunction with switching anti-staphylococcal prophylaxis
from flucloxacillin [16]. This protocol was successful in 10/
18 (56%) of patients. Garske et al. used a combination of
oral rifampicin and sodium fusidate for six months [17].
This protocol was successful in 5/7 (71%). These protocols
are relatively untested, have significant failure rates, require
sometimes unpleasant and lengthy therapy with potentially
toxic drugs, and give rise to legitimate concerns regarding
the emergence of antibiotic resistance. Therefore it would be
important to understand the risk factors associated with the
emergence of MRSA in patients with CF. We therefore
conducted a case-control study in the Regional Paediatric
and Adult CF Units to assess these risk factors.Table 1
Table showing statistical significance of risk factors between cases and
controls
Risk factor Cases Controls p Value
Mean Schwachman score 88.2 (82–95) 84.6 (27–100) 0.68
Mean Northern CXR score 7.3 (3–11) 6.3 (0–18) 0.25
Mean no. inpatient days (range) 19.8 (0–65) 5.5 (0–46) 0.0003T
Mean no. days amoxicillin 4.1 (0–14) 5.3 (0–28) 0.91
Mean no. days iv/oral
cephalosporins
42.7 (0–213) 15.4 (0–74) 0.04T
Mean no. days macrolides 6.3 (0–35) 2.5 (0–14) 0.27
Mean no. days colistin 52.0 (0–160) 24.8 (0–222) 0.09
Mean no. days ciprofloxacin 43.5 (0–152) 13.9 (0–125) 0.03T
Mean no. days other intravenous
(iv) anti-pseudomonal
h-lactams
10.5 (0–42) 10.4 (0–105) 0.41
% patients on flucloxacillin
prophylaxis
67% 67% 1.00
% patients with permanent iv
catheters
53% 30% 0.19
% patients with diabetes 13% 20% 0.70
% patients chronically colonised
with P. aeruginosa
20% 23% 1.00
% patients chronically colonised
with B. cepacia complex
7% 3% 0.56
% patients chronically colonised
with S. maltophilia
7% 0% 0.33
% patients chronically colonised
with Aspergillus species
40% 10% 0.04T
% patients DF508 homozygotes 53% 77% 0.17
% patients DF 508 heterozygotes 40% 17% 0.14
T Significant at pb0.05.2. Materials and methods
Between October and December 2002 clinical and
laboratory databases from both the Regional Paediatric
and Adult CF Units were retrospectively analysed to
identify patients from whom MRSA had been isolated
between 1992 and 2002 (cases). Two age-sex-matched
controls (patients who had never been MRSA-positive from
any site) were selected for each case. Age matching was
performed by selecting MRSA-negative patients who
appeared immediately before and after each case when a
list of clinic attendees was arranged in chronological order.
For each case the date of the respiratory sample from
which MRSA was first isolated was identified. The clinical
and laboratory records of each case and their matched
controls were then compared for the 12 months preceding
the date of first isolation. Data collected included hospital
admissions, length of stay, type and duration of antibiotic
therapy, routes of antibiotic administration, Schwachman
clinical and Northern chest X-ray scores, genotype, and the
presence of implantable medical devices such as Portocaths.
Patients were categorised as chronically colonised with
other CF pathogens using a standardised method [18].
Statistical analysis of results was performed using the
Mann–Whitney U-test when comparing the medians of
two independent samples and Fisher’s exact test for
categorical data. Significance was taken to occur at pb0.05.3. Results
Fifteen CF patients (nine female) were identified as
having respiratory cultures positive for MRSA at some time.
Ten were children (Age range at acquisition: 3 years, 10
months–14 years 7 months; median age 8 years 9 months)
and five were adults (Age range at acquisition: 20 years 2
months–32 years 4 months; median age 21 years 2 months).
Thirty age-sex-matched controls were therefore used as
comparators. Results for a number of risk factors and the
statistical analysis are shown in Table 1. Four significant
associations were identified: the total number of in-patient
days (19.8 versus 5.5, p=0.0003), the number of days of
therapy with ciprofloxacin (43.5 versus 13.9, p=0.03), the
number of days of therapy with cephalosporins (42.7 versus
15.4, p=0.04), and the number of patients chronically
infected with Aspergillus species (40% cases versus 10%
controls, p=0.04).4. Discussion
Four factors were significantly associated with acquis-
ition of MRSA by CF patients. The most significant factor
was the number of in-patient days (19.8 versus 5.5,
p=0.0003).
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hospital is not entirely clear because clinical and chest X-ray
(CXR) scores are not significantly different between the two
groups. The age range and overall clinical condition of the
patients shows that MRSA acquisition is not just confined to
older patients with the poorest clinical condition.
MRSA is still perceived as a hospital-acquired pathogen,
although recently there have been increasing reports of
strains that circulate predominantly in the community [19].
Further epidemiological studies would be required to
ascertain whether cases came into contact with other known
MRSA-positive patients prior to acquisition or if the strains
of MRSA identified in this study were nosocomial or
community-acquired strains.
The United Kingdom (UK) has national guidelines for
the control of MRSA in the hospital setting [20]. However,
they make no specific mention of appropriate management
of MRSA in CF units. The Cystic Fibrosis Trust in the UK
has published infection control guidance with respect to P.
aeruginosa but has yet to outline guidance for MRSA. It is
essential that all CF units have policies for the control of
MRSA and seek advice from their local Infection Control
Teams. All known MRSA-positive CF patients should be
managed accordingly to reduce the risk of transmission to
non-affected patients during admission. Handwashing and
appropriate use of isolation facilities are the main corner-
stones of such policies.
Two other significant factors were the number of days of
therapy with ciprofloxacin (43.5 versus 13.9, p=0.03) and
cephalosporins (42.7 versus 15.4, p=0.04). No other anti-
biotic classes were significantly associated with MRSA
acquisition. Several other studies have also identified these
antibiotics (or other quinolones) with an increased risk of
MRSA acquisition [4,5]. The reasons for this are unclear.
MRSA is inherently resistant to all h-lactam antibiotics,
including penicillins and cephalosporins. However, there
was no evidence of selective pressure being exerted by
penicillins. Some studies have shown that excretion of
quinolones and third generation cephalosporins in sweat
may increase resistance in skin isolates of Staphylococcus
epidermidis [21,22]. It is tempting to speculate that these
then act as a reservoir for the horizontal transfer of
resistance genes to S. aureus. Further studies are required
to ascertain if this is indeed the case.
The final significant factor identified in this study was
the number of patients chronically colonised with Aspergil-
lus species (40% cases versus 10% controls, p=0.04). The
association between chronic colonization with Aspergillus
species and other emerging pathogens in CF, such as
Stenotrophomonas maltophilia, has also been noted [23].
Why this association should occur is unclear. No significant
differences in chronic infection with other CF pathogens,
such as P. aeruginosa or Burkholderia cepacia complex
were observed. Previous studies have suggested an associ-
ation between colonisation with Aspergillus species and
residence in rural areas [24] but, to our knowledge, no studyhas implicated hospital admission as a risk factor for
colonisation with Aspergillus species. As they are fungi,
Aspergillus species are resistant to the antibacterial agents
used extensively in the management of patients with CF.
The selective pressure exerted by antibiotics may therefore
be selecting in favour of both MRSA and Aspergillus
species. Colonisation rates with other multi-resistant patho-
gens, such as S. maltophilia were also higher among cases
but this was not statistically significant.
There was no evidence to support that flucloxacillin
prophylaxis conferred an increased risk for MRSA acquis-
ition. The proportion receiving prophylaxis (67%) was equal
in both groups. This suggests that the policy of switching
from flucloxacillin to cephradine as a means of reducing
selective pressure in favour of MRSA [16] is misleading and
unlikely to reduce risks. There is also evidence that this
policy will actually increase the risk of colonisation with P.
aeruginosa. The use of first generation cephalosporins as
anti-Staphylococcal prophylaxis was associated with a P.
aeruginosa colonisation rate of 25.9% compared to 13.5%
with placebo [25].
This study showed that MRSA acquisition in CF patients
is associated with hospital admission and increased use of
certain classes of antibiotics, particularly ciprofloxacin and/
or cephalosporins. These findings are consistent with other
studies conducted in non-CF patient groups. Control of
MRSA acquisition by CF patients could therefore be
enhanced by minimising hospital admissions and judicious
use of those antibiotics exerting the greatest selective
pressure.Acknowledgements
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